Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) CEO Bobak Azamian sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $80.31, for a total value of $803,100.00. Following the sale, the chief executive officer owned 817,991 shares of the company’s stock, valued at approximately $65,692,857.21. This represents a 1.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tarsus Pharmaceuticals Price Performance
Shares of TARS traded down $0.48 during trading hours on Tuesday, reaching $78.20. The stock had a trading volume of 542,217 shares, compared to its average volume of 871,204. Tarsus Pharmaceuticals, Inc. has a 12 month low of $53.89 and a 12 month high of $91.53. The firm has a 50-day simple moving average of $74.60 and a 200 day simple moving average of $68.05. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.96 and a quick ratio of 1.94.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative return on equity of 24.51%. The business had revenue of $194.57 million during the quarter, compared to analyst estimates of $187.83 million. On average, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -15.64 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in TARS. BlackRock Inc. bought a new stake in Tarsus Pharmaceuticals during the second quarter worth $242,705,000. Jupiter Topco LLC bought a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at $176,834,000. Janus Henderson Group PLC grew its stake in Tarsus Pharmaceuticals by 16.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company’s stock valued at $157,223,000 after purchasing an additional 310,638 shares during the period. Bank of America Corp DE grew its stake in Tarsus Pharmaceuticals by 57.5% in the 1st quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock valued at $83,786,000 after purchasing an additional 436,271 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Tarsus Pharmaceuticals by 9.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 816,233 shares of the company’s stock valued at $64,164,000 after purchasing an additional 73,540 shares during the last quarter. 90.01% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
TARS has been the subject of several recent research reports. The Goldman Sachs Group initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, September 24th. They set a “buy” rating and a $116.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, October 15th. Guggenheim lifted their price target on Tarsus Pharmaceuticals from $89.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Barclays assumed coverage on Tarsus Pharmaceuticals in a report on Wednesday, September 16th. They set an “overweight” rating and a $110.00 price objective for the company. Finally, Mizuho dropped their target price on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $104.57.
Get Our Latest Analysis on TARS
Tarsus Pharmaceuticals Company Profile
Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for diseases with significant unmet medical needs, particularly in eye care. The company’s work includes therapies targeting Demodex mites, microscopic parasites associated with certain eye conditions. Its lead product, XDEMVY (lotilaner ophthalmic solution), is an FDA-approved prescription treatment for Demodex blepharitis, an eyelid condition. Tarsus has also evaluated lotilaner-based candidates for other conditions, including ocular rosacea and Lyme disease prevention.
Featured Articles
- Five stocks we like better than Tarsus Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
